Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015672 (fatigue)
 51,768 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To assess the causes of excessive fatigue among patients who have recovered from cranio-cerebral injury (CCI) nineteen patients and fourteen healthy controls underwent pulmonary function testing at rest and cardiopulmonary evaluation during two submaximal exercise work-loads. Total lung capacity, vital capacity and forced expired volume were reduced by 25--40% among the patients. Functional residual capacity was normal. No improvement was elicited by inhalation of Ventolin and bronchoconstriction could thus be excluded. The above pattern may result from either decreased compliance of the chest wall or from weak (or non-coordinated) respiratory musculature. Exercise heart rate, minute ventilation and ventilatory equivalent were higher, and O2 pulse lower, among the CCI patients compared with the controls. This indicates lower circulatory and ventilatory efficiency during exercise among the patients, possibly due to habitual hypoactivity and detraining.
 ...
PMID:Pulmonary functions and responses to exercise of patients following cranio cerebral injury. 67 82

This study was designed to examine the effects of acute inhalation of the bronchodilator, albuterol (Proventil, Schering Corp.), on high intensity power output. Fifteen healthy nonasthmatic subjects (eight male, seven female, 18-33 yr) performed four supramaximal 15-s rides on a bicycle ergometer. Rides were arranged in pairs with a 10-min rest interval. Each pair of rides was preceded by a 5-min warm-up. Sessions were separated by a minimum of 48 h. The study design was fully randomized and double blind. Ten minutes prior to each pair of rides subjects inhaled two metered doses (180 micrograms) of albuterol (A) or a placebo (P). Individual ANOVAs revealed a significant difference between the A and P treatment for peak power (A = 886.6 W, P = 858.3 W) and fatigue (A = 27.2%, P = 24.4%). Mean changes in FEF25-75% (A = 0.712, P = 0.040 l.s-1), FEV1.0 (A = 0.188, P = 0.007 l), and PEF (A = 0.573, P = -0.155 l.s-1) were also statistically significant; however, these changes did not correlate to the anaerobic performance changes. No significant differences were found between treatments for heart rate increases resulting from the power test (A = 56.73 bpm, P = 53.20 bpm). These results indicate an ergogenic effect of the bronchodilator on short-term power output independent of impact on respiratory smooth muscle, with no effect on cardiac response.
 ...
PMID:Effects of acute inhalation of the bronchodilator, albuterol, on power output. 131 86